
Lucid Diagnostics (LUCD) Stock Forecast & Price Target
Lucid Diagnostics (LUCD) Analyst Ratings
Bulls say
Lucid Diagnostics Inc. demonstrated a positive trajectory in test volume, with EsoGuard tests increasing by 2% year-over-year to 2,841 in 3Q25, reflecting consistent growth despite fluctuations in prior quarters. The company's ongoing efforts to expand insurance coverage, particularly with Medicare, are poised to accelerate revenue growth, narrowing the gap between revenue and test volume increases. Furthermore, a favorable outcome from the MolDX CAC meeting indicates promising potential for enhanced coverage and engagement, suggesting significant upside potential for Lucid Diagnostics amid its commercialization efforts.
Bears say
Lucid Diagnostics experienced a disappointing performance in 3Q25, with revenue falling below consensus expectations while the company reported a stable cash burn and a pro forma net loss of $10.3 million, which was greater than its previous projections. The decline in EsoGuard test processing, evidenced by a drop from 3,034 tests in Q1 to 2,756 tests in Q2, raises concerns about market adoption and demand for their primary product. Additionally, multiple risks, such as potential insurance coverage challenges, ineffective marketing strategies, and increasing competition, could further hinder the company’s financial stability and growth prospects.
This aggregate rating is based on analysts' research of Lucid Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Lucid Diagnostics (LUCD) Analyst Forecast & Price Prediction
Start investing in Lucid Diagnostics (LUCD)
Order type
Buy in
Order amount
Est. shares
0 shares